In our study, 62 participants were receiving biological therapy at the time of infection, as described in Table 2: anti-IgE (omalizumab) 30.6%, anti-IL5 (mepolizumab) 25.8%, anti-IL5R (benralizumab) 19.4%, and anti-IL4/IL13R (dupilumab) 24.2%. This evidence concerns the gene IGHE and infection.